Kolon Life Science Inc.

Total Valuation

Kolon Life Science Inc. carries a market capitalization of 627.38B, placing it among publicly traded companies globally. Its enterprise value stands at 816.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Kolon Life Science Inc. trades at a trailing price-to-earnings ratio of 20.23. The price-to-sales ratio is 3.34, and the price-to-book ratio stands at -4.06.

Enterprise Valuation

On an enterprise value basis, Kolon Life Science Inc. trades at an EV/EBITDA multiple of 22.06 and an EV/FCF ratio of 21.92. The EV/Sales ratio of 3.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.06 provides insight into valuation relative to core operating earnings.

Financial Position

Kolon Life Science Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.20, indicating elevated leverage, while an interest coverage ratio of 5.23 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Kolon Life Science Inc. has paid 764.03M in income taxes, reflecting an effective tax rate of 2.12.

Stock Price Statistics

Kolon Life Science Inc.'s stock has gained approximately 74.13793% over the past 52 weeks. The 50-day moving average sits at 56,877.00, while the 200-day moving average is 48,144.25.

Income Statement

Over the trailing twelve months, Kolon Life Science Inc. generated 213.81B in revenue and converted that into 35.33B in net income, yielding earnings per share of 2,634.96. EBITDA reached 37.00B, while operating income came in at 37.00B.

Balance Sheet

Kolon Life Science Inc. holds 9.61B in cash and equivalents against 111.38B in total debt, resulting in a net debt position of 99.75B. Total book value stands at -176.15B, with working capital of -43.27B providing operational flexibility.

Cash Flow

Kolon Life Science Inc. produced 2.78B in operating cash flow over the past twelve months. After subtracting -27.53B in capital expenditures, free cash flow totaled -24.76B - equivalent to -1,960.71 per share.

Margins

Kolon Life Science Inc. operates with a gross margin of 28.14, reflecting its pricing power and cost economics. The operating margin of 17.31 and net profit margin of 16.52 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Kolon Life Science Inc.'s most recent stock split took place on December 27, 2017 with a 2:3 split ratio.

Scores

Kolon Life Science Inc. posts an Altman Z-Score of 1.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.